Remus Pharmaceuticals Limited (NSEI: REMUS)
Salud · Proveedores y servicios sanitarios · IN
810,90 Rs
-1,11 % hoy · +10,8 % 1 año
Remus Pharmaceuticals Limited (NSEI: REMUS) opera en la industria de proveedores y servicios sanitarios dentro del sector salud. Su valor en bolsa es de 101,34 M $ y tiene 69 empleados.
En los últimos doce meses la acción ha subido un 10,8 % y ha cotizado entre 580,00 y 1,04 mil.
Tweenvest puntúa a Remus Pharmaceuticals Limited en cuatro factores: calidad 65/100, valor 82/100, crecimiento 98/100, dividendo 42/100. Su punto más fuerte es crecimiento.
Evolución de la cotización de REMUS
Cifras clave
- Capitalización
- 101,34 M $
- Ingresos (últ. 12 m)
- 111,34 M $
- PER
- 24,00
- BPA
- 34,82
- Rent. por dividendo
- 0,12 %
- Beta (5 años)
- 0,36
- Máximo 52 semanas
- 1039,00 Rs
- Mínimo 52 semanas
- 580,00 Rs
- Volumen medio (3 m)
- —
- Acciones en circulación
- 11,78 M
- Empleados
- 69
- Próximos resultados
- —
Sobre Remus Pharmaceuticals Limited
Remus Pharmaceuticals Ltd. is a pharmaceutical company engaged in the marketing, trading, and distribution of finished dosage formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company's diverse product portfolio, exceeding 600 offerings, includes tablets, capsules, injections, creams, gels, eye drops, and various other dosage forms. Remus Pharmaceuticals focuses on therapeutic categories such as Critical Care, Oncology, Nephrology, Central Nervous System, Cardiology, Diabetics, Antibiotics, Immunosuppressants, Anti-inflammatory, Antifungal, Antipsychotic, Antiretroviral, Dermatology, Urology, and products for vitamin deficiency. The company primarily targets export markets, with significant operations in the Middle East, Africa, Southeast Asia, Latin America, and other emerging global markets. Leveraging an asset-light business model, Remus Pharmaceuticals collaborates with third-party and contract manufacturers, while also possessing manufacturing capabilities in India and the USA, to produce and distribute cost-effective generic alternatives. Additionally, the company provides technical and consultancy services for preparing product dossiers for international registration and engages in research and development for generic drugs and clinical trials.
- ISIN
- INE0O5T01011
- Fundada en
- 2015
- Cotiza desde
- 29 may 2023
- Bolsa
- National Stock Exchange of India
- Divisa
- INR
Otras empresas de proveedores y servicios sanitarios
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| BenQ BM Holding Cayman Corp.SEHK: 2581 | 104,77 M $ | 2,64 HK$ | -0,94 % |
| Business Alignment Public Company LimitedSET: BIZ | 103,71 M $ | 5,85 ฿ | -0,85 % |
| Nakamoto Inc.NasdaqGM: NAKA | 103,61 M $ | 5,79 $ | -7,36 % |
| Shifa International Hospitals LimitedKASE: SHFA | 102,10 M $ | 446,16 PKRs | +0,15 % |
| Medius Holdings Co., Ltd.TSE: 3154 | 100,98 M $ | 726,00 ¥ | +0,69 % |
| Wenzhou Kangning Hospital Co., Ltd.SEHK: 2120 | 98,56 M $ | 11,30 HK$ | +0,89 % |
| WeLeader Biomedical Co., Ltd.TPEX: 7713 | 97,55 M $ | 70,60 NT$ | 0,00 % |
| Nozha International HospitalCASE: NINH | 96,11 M $ | 17,12 EGP | -0,93 % |
Ver todas las empresas de proveedores y servicios sanitarios →